News | January 18, 2024
NATCO invests US$ 2 million in Cellogen Therapeutics
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Launch innovative vitamin sublingual sprays
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Subscribe To Our Newsletter & Stay Updated
